Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31540767 | 0.89 | TAAR1 (0.47) | PNMTTAAR1HDAC1MAOBCHRM2 | |
| SCHEMBL7250935 | 0.85 | CHRM2 (0.55) | PNMTTAAR1MAOBCHRM2ALDH1A1 | |
| SCHEMBL6719108 | 0.84 | ALDH1A1 (0.42) | HDAC1CHRM2ALDH1A1ANPEPERAP2 | |
| SCHEMBL184010 | 0.80 | OXTR (0.57) | CHRM2ALDH1A1 | |
| SCHEMBL625849 | 0.77 | ALDH1A1 (0.47) | HDAC1ALDH1A1 | |
| SCHEMBL185074 | 0.76 | OXTR (0.57) | CHRM2ALDH1A1 | |
| SCHEMBL625735 | 0.75 | CHRM2 (0.48) | TAAR1CHRM2 | |
| SCHEMBL111874 | 0.75 | PNMT (0.56) | PNMTTAAR1MAOBHRH3 | |
| SCHEMBL7244890 | 0.74 | LOXL2 (0.67) | TAAR1MAOBCHRM2TPSAB1 | |
| SCHEMBL6714941 | 0.73 | CHRM2 (0.57) | HDAC1CHRM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-9006392-B2 | Actagardine derivatives, and pharmaceutical use thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-9006392-B2 | Actagardine derivatives, and pharmaceutical use thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-04-14 | — | — | US | disclosed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| WO-2012020219-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2011095769-A1 | ACTAGARDINE DERIVATIVES, AND PHARMACEUTICAL USE THEREOF | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | PNMT 4344/4885TAAR1 1700/4885HDAC1 3232/4885 |
| US-20120302728-A1 | Actagardine Derivatives, and Pharmaceutical Use Thereof | GALR2, GALR1, GALR3 | PNMT 2317/4885TAAR1 373/4885HDAC1 4758/4885 |
| US-20110294723-A1 | Compounds | SLC11A2, SDHA, SDHB | PNMT 3238/4885TAAR1 4497/4885HDAC1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.